SAN DIEGO--(BUSINESS WIRE)--June 16, 2006--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH - News) announced today that its scientists presented data detailing the oral activity of five candidate compounds in preclinical animal models relevant to cystic fibrosis (CF) at the 29th European Cystic Fibrosis Conference being held June 15-18 in Copenhagen, Denmark.
